Education
About Us
Working with TipRanks
Follow Us
TG Therapeutics (TGTX)
NASDAQ:TGTX
Earnings Data
Report Date
Aug 05, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.2Last Year’s EPS
0.04Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 05, 2025
|% Change Since: -22.05%
|Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in BRIUMVI sales, increased revenue guidance, and advancements in the pipeline, suggesting strong commercial and financial performance. While there were some concerns about manufacturing expenses and potential tariffs, these were not expected to significantly impact overall performance.Company Guidance
During TG Therapeutics' first quarter 2025 conference call, the company reported strong financial performance, with BRIUMVI US net sales reaching approximately $119.7 million, reflecting a 137% year-over-year growth and 16% sequential quarter-over-quarter growth. This performance led to an increase in full-year 2025 US net revenue guidance from $525 million to $560 million. The company highlighted robust patient demand, with the highest months of new patient enrollment since launch, and a growing number of repeat prescriptions. The operating expenses for the quarter, excluding non-cash items, were about $82 million, tracking slightly ahead of the annual guidance of $300 million primarily due to manufacturing investments. The company reported a GAAP net income of approximately $5 million for the quarter, supported by a strong cash position of $276 million. Key strategic initiatives discussed included a direct-to-patient television campaign and ongoing development of a subcutaneous formulation of BRIUMVI, with plans to launch a pivotal trial this year.BRIUMVI US Net Sales Growth
BRIUMVI US net sales reached nearly $120 million in the first quarter, exceeding expectations and marking a 137% year-over-year growth and 16% sequential quarter-over-quarter growth.
Raising Full-Year Revenue Guidance
Based on strong performance, TG Therapeutics raised their full-year 2025 US net revenue guidance for BRIUMVI to $560 million from a previous $525 million.
Pipeline and Innovation Strategy
TG Therapeutics is advancing a self-administered subcutaneous version of BRIUMVI and has initiated efforts in Myasthenia Gravis and azer-cel, a CD19 CAR-T cell therapy for progressive forms of MS.
Commercial Strategy Execution
The company reported strong commercial execution, with high repeat prescriptions and increasing prescriber confidence, leading to a robust start in 2025.
Financial Stability
TG Therapeutics ended the quarter with $276 million in cash, cash equivalents, and investment securities, indicating a strong financial position.
---
TGTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TGTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| May 05, 2025 | $43.44 | $37.68 | -13.26% |
| Mar 03, 2025 | $30.09 | $34.42 | +14.39% |
| Nov 04, 2024 | $26.90 | $24.36 | -9.44% |
| Aug 06, 2024 | $17.21 | $20.58 | +19.58% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does TG Therapeutics (TGTX) report earnings?
TG Therapeutics (TGTX) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
What is TG Therapeutics (TGTX) earnings time?
TG Therapeutics (TGTX) earnings time is at Aug 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TGTX EPS forecast?
TGTX EPS forecast for the fiscal quarter 2025 (Q2) is 0.2.
---